James C Dodge

Summary

Affiliation: Genzyme Corporation
Country: USA

Publications

  1. pmc Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease
    James C Dodge
    Genzyme Corporation, One Mountain Road, Framingham, MA 01701, USA
    Proc Natl Acad Sci U S A 102:17822-7. 2005
  2. pmc Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis
    James C Dodge
    Genzyme, Framingham, MA 01701 9322, USA
    Proc Natl Acad Sci U S A 110:10812-7. 2013
  3. pmc AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice
    James C Dodge
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Mol Ther 18:2075-84. 2010
  4. doi request reprint Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease
    James C Dodge
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Exp Neurol 215:349-57. 2009
  5. pmc Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity
    James C Dodge
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Mol Ther 16:1056-64. 2008
  6. ncbi request reprint Noradrenergic regulation of prolactin secretion at the level of the paraventricular nucleus of the hypothalamus: functional significance of the alpha-1b and beta-adrenergic receptor subtypes
    James C Dodge
    Behavioral Neuroscience Program, Psychology Department, SUNY at Buffalo, USA
    Brain Res 1016:240-6. 2004
  7. pmc Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse
    Marco A Passini
    Genzyme Corporation, Framingham, MA 01701, USA
    Proc Natl Acad Sci U S A 104:9505-10. 2007
  8. ncbi request reprint AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease
    Marco A Passini
    Neuroscience, Genzyme Corporation, One Mountain Road, Framingham, MA 01701, USA
    Mol Ther 11:754-62. 2005
  9. ncbi request reprint Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse
    Wendy W Yang
    Genzyme Corporation, One Mountain Road, Framingham, MA 01701 9322, USA
    Exp Neurol 207:258-66. 2007
  10. doi request reprint Relationship between neuropathology and disease progression in the SOD1(G93A) ALS mouse
    Wendy W Yang
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701 9322, USA
    Exp Neurol 227:287-95. 2011

Collaborators

Detail Information

Publications23

  1. pmc Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease
    James C Dodge
    Genzyme Corporation, One Mountain Road, Framingham, MA 01701, USA
    Proc Natl Acad Sci U S A 102:17822-7. 2005
    ..Our results support the continued development of AAV based vectors for gene therapy of the CNS manifestations in Niemann-Pick type A disease...
  2. pmc Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis
    James C Dodge
    Genzyme, Framingham, MA 01701 9322, USA
    Proc Natl Acad Sci U S A 110:10812-7. 2013
    ..Collectively, these data provide insights into the pathogenesis of ALS as well as potential targets for drug development. ..
  3. pmc AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice
    James C Dodge
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Mol Ther 18:2075-84. 2010
    ..These findings support the continued investigation of trophic factor-based therapies that target the CNS as a potential treatment of ALS...
  4. doi request reprint Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease
    James C Dodge
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Exp Neurol 215:349-57. 2009
    ..These findings support the continued exploration of ICV delivery of recombinant lysosomal enzymes as a therapeutic modality for LSDs such as NPA that manifests substrate accumulation within the CNS...
  5. pmc Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity
    James C Dodge
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Mol Ther 16:1056-64. 2008
    ..Our findings highlight an innovative approach for delivering IGF-1 to the CNS...
  6. ncbi request reprint Noradrenergic regulation of prolactin secretion at the level of the paraventricular nucleus of the hypothalamus: functional significance of the alpha-1b and beta-adrenergic receptor subtypes
    James C Dodge
    Behavioral Neuroscience Program, Psychology Department, SUNY at Buffalo, USA
    Brain Res 1016:240-6. 2004
    ..The results of this study indicate that both the alpha-1b and beta-adrenergic receptor subtypes have a significant role in regulating circulating levels of prolactin at the level of the PVN in the Siberian hamster...
  7. pmc Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse
    Marco A Passini
    Genzyme Corporation, Framingham, MA 01701, USA
    Proc Natl Acad Sci U S A 104:9505-10. 2007
    ..These data demonstrate that combination therapy is a promising therapeutic modality for treating NPD and suggest a potential strategy for treating disease indications that cause both visceral and CNS pathologies...
  8. ncbi request reprint AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease
    Marco A Passini
    Neuroscience, Genzyme Corporation, One Mountain Road, Framingham, MA 01701, USA
    Mol Ther 11:754-62. 2005
    ..These findings show that the ASMKO brain is responsive to ASM replacement and that retrograde transport of AAV2 functions as a platform for widespread gene delivery and reversal of pathology in affected brain...
  9. ncbi request reprint Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse
    Wendy W Yang
    Genzyme Corporation, One Mountain Road, Framingham, MA 01701 9322, USA
    Exp Neurol 207:258-66. 2007
    ..These results indicate that intraparenchymal injection of hASM is associated with minimal toxicity and can lead to regional reductions in storage pathology in the ASMKO mouse...
  10. doi request reprint Relationship between neuropathology and disease progression in the SOD1(G93A) ALS mouse
    Wendy W Yang
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701 9322, USA
    Exp Neurol 227:287-95. 2011
    ..Hence, our findings support a role for astrocytes in modulating the progression of non-cell autonomous degeneration of motor neurons, with microglia playing a role in clearing degenerating neurons...
  11. pmc Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A
    Jie Bu
    Rare Diseases Division, Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Mol Ther 20:1893-901. 2012
    ..The information from this study might help design new AAV-mediated enzyme replacement protocols for NPA and other neuronopathic LSDs in future clinical trials...
  12. ncbi request reprint Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease
    Mario A Cabrera-Salazar
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Mol Ther 15:1782-8. 2007
    ..These data illustrate the importance of early intervention for enhanced therapeutic benefit, which may provide guidance in designing novel treatment strategies for cLINCL patients...
  13. ncbi request reprint Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis
    Marco A Passini
    Neuroscience, Genzyme Corporation, Framingham, Massachusetts 01701, USA
    J Neurosci 26:1334-42. 2006
    ..This study demonstrates that AAV-mediated TPP1 enzyme replacement corrects the hallmark cellular pathologies of cLINCL in the mouse model and raises the possibility of using AAV gene therapy to treat cLINCL patients...
  14. pmc Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies
    Christopher M Treleaven
    Genzyme, a Sanofi Company, Framingham, Massachusetts 01701 9322, USA
    Mol Ther 20:1713-23. 2012
    ..These findings support the continued development of AAV-based therapies for the treatment of neurological disorders...
  15. pmc Disease progression in a mouse model of amyotrophic lateral sclerosis: the influence of chronic stress and corticosterone
    Jonathan A Fidler
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701 9322, USA
    FASEB J 25:4369-77. 2011
    ..680; females: r(2)=0.552) in ALS mice. These results suggest that stress is capable of accelerating disease progression and that strategies that modulate glucocorticoid metabolism might be a viable treatment approach for ALS...
  16. pmc Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
    S Pablo Sardi
    Genzyme, a Sanofi Company, Framingham, MA 01701, USA
    Proc Natl Acad Sci U S A 110:3537-42. 2013
    ..Hence, increasing glucocerebrosidase activity in the CNS represents a potential therapeutic strategy for GBA1-related and non-GBA1-associated synucleinopathies, including PD...
  17. pmc Comparative analysis of acid sphingomyelinase distribution in the CNS of rats and mice following intracerebroventricular delivery
    Christopher M Treleaven
    Genzyme Corporation, Framingham, Massachusetts, United States of America
    PLoS ONE 6:e16313. 2011
    ..Collectively, these data suggest that the efficacy observed following ICV delivery of hASM in ASMKO mice could be scaled to CNS of the rat...
  18. ncbi request reprint Male-induced estrus synchronization in the female Siberian hamster (Phodopus sungorus sungorus)
    James C Dodge
    Behavioral Neuroscience Program, Department of Psychology, University at Buffalo, Buffalo, NY, USA
    Physiol Behav 77:227-31. 2002
    ..Therefore, we found that not only do male Siberian hamsters emit chemical signals that induce estrus synchronization, but also that this ability is likely to be androgen dependent...
  19. doi request reprint Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion
    Robin J Ziegler
    Genzyme Corporation, Framingham, MA, USA
    Exp Neurol 231:261-71. 2011
    ..Additional optimization of an ICV delivery approach may provide a therapeutic option for LSDs with neurologic involvement...
  20. ncbi request reprint 5HT and 5HIAA dialysate levels within the arcuate nucleus of the hypothalamus: relationship with photoperiod-driven differences in serum prolactin and luteinizing hormone in the Siberian hamster
    James C Dodge
    Behavioral Neuroscience Division, Psychology Department, SUNY at Buffalo, NY, USA
    Brain Res 946:171-8. 2002
    ..Our results indicate that elevated 5HT and 5HIAA dialysate levels within the ARC may regulate photoperiod effects upon LH and PRL secretion, but not the preovulatory surges of LH and PRL...
  21. ncbi request reprint Infusion of alpha-2-adrenergic agents into the paraventricular and arcuate nuclei of the hypothalamus in the Siberian hamster: opposing effects on basal prolactin
    James C Dodge
    Behavioral Neuroscience Division, Psychology Department, State University of New York at Buffalo, Buffalo, N Y, USA
    Neuroendocrinology 75:175-84. 2002
    ....
  22. pmc Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice
    Richard L Sidman
    Department of Neurology RLS, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Neuropathol Exp Neurol 67:803-18. 2008
    ..A better understanding of the basis for clinical manifestations is needed to correlate CNS pathology with Pompe disease manifestations...
  23. doi request reprint Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis
    Michael Chang
    Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, Iowa 52242, USA
    Mol Ther 16:649-56. 2008
    ..This data demonstrates that intraventricular enzyme delivery to the CNS is feasible and may be of therapeutic value...